Home / Publications / Pain Research Forum / Papers of the Week / Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial.
Although erenumab has demonstrated significant reduction in migraine frequency and improved quality of life in studies lasting 3-12 months, little is known about long-term therapy.
